Portable MRI shows promise for monitoring Alzheimer’s treatment

Published 28/07/2025, 13:28
Portable MRI shows promise for monitoring Alzheimer’s treatment

TORONTO - Hyperfine, Inc. (NASDAQ:HYPR), a medical technology company with a market capitalization of $84 million and strong financial health according to InvestingPro metrics, reported promising interim results from its CARE PMR study showing that its portable Swoop MRI system achieved 100% sensitivity in detecting ARIA-E, a side effect in patients receiving amyloid-targeting Alzheimer’s therapies.

The study, presented at the 2025 Alzheimer’s Association International Conference in Toronto, included 31 Alzheimer’s patients undergoing Lecanemab therapy who were scanned with both the Swoop system and conventional high-field MRI within a one-week period.

ARIA-E, characterized by cerebral edema, is a condition that requires monitoring in patients receiving FDA-approved amyloid-targeting therapies. Current protocols require multiple MRI scans throughout treatment, which can be costly and logistically challenging.

Dr. Tammie Benzinger, principal investigator from Washington University School of Medicine in St. Louis, noted, "This research could help alleviate the burden on families and facilities and improve overall access to care."

The portable, ultra-low-field Swoop system could potentially serve as a triage tool at points of care such as neurology offices and infusion clinics, though researchers indicated high-field MRI may still be necessary for comprehensive evaluation in some cases. The company’s stock has shown strong momentum, with an 11.47% return over the past week, while maintaining a healthy balance sheet with more cash than debt and a current ratio of 6.07.

The CARE PMR study is funded by the Alzheimer’s Association and the American Society of Neuroradiology to assess the clinical utility of using the Swoop system to detect amyloid-related imaging abnormalities in Alzheimer’s patients.

Hyperfine’s Swoop system is FDA-cleared for brain imaging of patients of all ages. The company aims to expand access to diagnostic imaging by providing portable MRI technology at the point of care.

This article is based on a press release statement from Hyperfine, Inc. With the company’s next earnings report due on August 7, 2025, investors seeking deeper insights can access comprehensive analysis and additional ProTips through InvestingPro’s detailed research reports, which transform complex financial data into actionable intelligence for smarter investment decisions.

In other recent news, Hyperfine, Inc. reported its first-quarter 2025 earnings, revealing a significant shortfall in both earnings per share and revenue forecasts. The company posted a net loss of $9.4 million, or $0.12 per share, which was slightly below the expected EPS of -$0.1167. Revenue was $2.1 million, missing the anticipated $2.89 million. Despite these financial setbacks, Hyperfine has been active in launching new products and updates. The company began rolling out its FDA-cleared Optive AI™ software to enhance its Swoop® portable MRI systems. This software aims to improve image quality by refining noise cancellation and other imaging processes. Additionally, Hyperfine announced the first commercial sales of its next-generation Swoop systems to two hospitals in the northeastern United States. These developments follow the FDA clearance of its latest portable MRI scanner, which promises improved resolution and faster acquisition times.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.